Home › Funds › Redmile Group, LLC › EPRX

Redmile Group, LLC position in EPRX

EUPRAXIA PHARMACEUTICALS INC · Health Care

Redmile Group, LLC reported holding 611,400 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$4.0M, representing 0.27% of its reported portfolio and ranking #35 among its reported holdings. Redmile Group, LLC has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)611.40K sh
Reported value held$4.04M
Portfolio Weight0.27%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Redmile Group, LLC's EPRX position evolved

Redmile Group, LLC first disclosed a stake in EPRX in Q1 2026 at 700,000 shares (US$5.1M). Across 2 filings, Redmile Group, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 611,400 shares valued at US$4.0M — a reduction of -88,600 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 700.00K $5.07M New
Q2 2026 611.40K $4.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EPRX and 13F data

EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 69 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$8.9M), PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EPRX

All EPRX fund holders →

FAQ

How long has Redmile Group, LLC held EPRX?

Redmile Group, LLC has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Redmile Group, LLC's current position in EPRX?

As of Q2 2026, Redmile Group, LLC holds 611.40K shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $4.04M, representing 0.27% of its reported portfolio and ranking #35.

Has Redmile Group, LLC been buying or selling EPRX?

In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in EPRX.

Which other funds hold EPRX?

Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.